MedTrace Logo

Post Authorisation Safety Study With Raxone in LHON Patients

NCT02771379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 229

Last updated 2021-07-16

No results posted yet for this study

Summary

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®.

No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.

Conditions

  • Leber's Hereditary Optic Neuropathy (LHON)

Interventions

DRUG

Idebenone

Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.

Sponsors & Collaborators

  • Santhera Pharmaceuticals

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2021-04-16
Completion
2021-04-16

Countries

  • Austria
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771379 on ClinicalTrials.gov